title: Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1.
abstract: Breast cancer metastasis suppressor 1 (BRMS1) inhibits the ability of multiple human and murine cancer cell lines to metastasize to lymph nodes, bones and lungs. Comparison of mRNA expression in metastatic MDA-MB-435 human carcinoma cells (435) and metastasis-suppressed BRMS1 transfectants (435/BRMS1) showed a marked (>90%) reduction of osteopontin (OPN) mRNA and protein expression in BRMS1-overexpressing cells. OPN expression is associated with disease progression in patients, with higher levels of OPN produced by cancer cells associated with poorer patient survival. Furthermore, OPN has been suggested to promote survival of cancer cells in response to stress, although the mechanisms by which this may occur remain poorly understood. This study tested the hypothesis that re-expression of OPN in metastasis-suppressed 435/BRMS1 cells would reverse metastasis suppression and confer protection from stress-induced apoptosis. A stable pooled population of OPN overexpressing 435/BRMS1 cells was created (435/BRMS1/OPN). OPN re-expression did not affect in vitro cell growth rates; however, increased anchorage independent growth/survival and protection from hypoxia-induced apoptosis was observed (p < 0.05). In vivo, OPN re-expression in BRMS1 transfected cells did not affect in vivo primary tumor growth but did increase the incidence of spontaneous metastasis to lymph nodes and lungs in mice. These novel findings suggest that OPN downregulation by BRMS1 may be responsible, at least in part, for BRMS1-mediated metastasis suppression by sensitizing cancer cells to stress induced apoptosis. These studies clarify one mechanism by which BRMS1 can suppress metastasis.
authors.affiliation: London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
authors.forename: Benjamin D
authors.initials: BD
authors.lastname: Hedley
authors.forename: Danny R
authors.initials: DR
authors.lastname: Welch
authors.forename: Alison L
authors.initials: AL
authors.lastname: Allan
authors.forename: Waleed
authors.initials: W
authors.lastname: Al-Katib
authors.forename: David W
authors.initials: DW
authors.lastname: Dales
authors.forename: Carl O
authors.initials: CO
authors.lastname: Postenka
authors.forename: Graham
authors.initials: G
authors.lastname: Casey
authors.forename: Ian C
authors.initials: IC
authors.lastname: Macdonald
authors.forename: Ann F
authors.initials: AF
authors.lastname: Chambers
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology*; D000818:Animals; D017209:Apoptosis; D015152:Blotting, Northern; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D049109:Cell Proliferation; D015536:Down-Regulation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D009363:Neoplasm Proteins / Q000378:metabolism*; D053495:Osteopontin / Q000378:metabolism*; D012097:Repressor Proteins
chemical_list: C410024:BRMS1 protein, human; D009363:Neoplasm Proteins; D012097:Repressor Proteins; D053495:Osteopontin